STTR Phase I: A therapeutic molecule for COVID-19
- Funded by National Science Foundation (NSF)
- Total publications:0 publications
Grant number: 2035422
Grant search
Key facts
Disease
COVID-19Start & end year
20212022Known Financial Commitments (USD)
$256,000Funder
National Science Foundation (NSF)Principal Investigator
Martin LowResearch Location
United States of AmericaLead Research Institution
ERADIVIR INCResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
Innovation
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The broader impact of this Small Business Technology Transfer (STTR) Phase I project is to provide a therapeutic solution for coronavirus pandemics. Coronaviruses have been implicated in several outbreaks, including prior SARS and MERS. The proposed therapeutic will inhibit the virus's ability to replicate and elicit the body's immune system to kill the virus. In addition, this research can be applied to solutions for other viruses including RSV, hepatitis B and HIV/AIDS.
The proposed project will advance a method integrating vaccines, small molecule inhibitors, and antibodies. This project will identify a small molecule that targets and binds to the virus, then link it to a small payload that signals the body's immune system. This project will identify and develop a targeting molecule that can bind effectively to multiple strains of the coronavirus and a payload that promotes an appropriate immune response.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
The proposed project will advance a method integrating vaccines, small molecule inhibitors, and antibodies. This project will identify a small molecule that targets and binds to the virus, then link it to a small payload that signals the body's immune system. This project will identify and develop a targeting molecule that can bind effectively to multiple strains of the coronavirus and a payload that promotes an appropriate immune response.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.